News

A new study into how four types of COVID-19 vaccines prepare the body to fight SARS-CoV-2 is the first in history to compare how three different vaccine platforms trigger an immune response against the same pathogen.

An anti-inflammatory therapeutic used to treat inflammatory bowel disease has been associated with increased T-cell activity after vaccination against COVID-19.

Novel cancer vaccine design stimulates a coordinated attack by both T cells and natural killer cells that prevents tumor metastasis in mice.

A next-generation sequence analysis of human endogenous retrovirus integration sites has revealed that ancient retroviral genes are expressed in early embryos, cancer stem cells and induced pluripotent stem cells.

A new antibiotic, synthesized at The Rockefeller University and derived from computer models of bacterial gene products, appears to neutralize even drug-resistant bacteria.

A nanoparticle vaccine that combines the spike protein and its stem subunit promotes a broader immune response that is sustained for at least four months, a new study shows.

Researchers running the Com-COV program have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15.

Most Cas9s are too big to be fitted into popular genome therapy vectors, such as the adenovirus-associated virus (AAV). Cornell scientists provide an explanation for how this problem is solved by nature: they define with atomic precision how a transposon-derived system edits DNA in RNA-guided fashion.

Even vaccinated people with mild breakthrough COVID-19 infections can experience debilitating, lingering symptoms that affect the heart, brain, lungs and other parts of the body, according to new research from Washington University School of Medicine in St. Louis and the Veterans Affairs St. Louis Health Care System.

An article explains why we should not rush to mass-immunize young children and how a delayed immunization could be beneficial in offering a more suitable vaccine formulation for children.